Search research articles
Contact Us
Filters
Showing results (481-490 of 651) with videos related to
Page
of 66
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
November 1, 1993
Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas
P Robberecht, P Vertongen, B Velkeniers, et al.
European Journal of Biochemistry
|
January 30, 1991
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes
P Gourlet, M C Woussen-Colle, P Robberecht, et al.
Human Molecular Genetics
|
December 10, 2019
Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy
Antina de Boer, Annet Storm, Maricel Gomez-Soler, et al.
The New England Journal of Medicine
|
June 11, 2005
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
Gert Van Assche, Marc Van Ranst, Raf Sciot, et al.
FEBS Letters
|
March 12, 1990
Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J
L Buscail, P Gourlet, A Cauvin, et al.
Peptides
|
July 1, 1990
The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK
A Cauvin, L Buscail, P Gourlet, et al.
British Journal of Pharmacology
|
June 24, 2000
Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition
J Van Rampelbergh, M G Juarranz, J Perret, et al.
Molecular Pharmacology
|
September 1, 1983
The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors
P Robberecht, M Delhaye, G Taton, et al.
Cellular Signalling
|
December 1, 2001
Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors
M G Juarranz, O Bolaños, I Gutiérrez-Cañas, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
February 1, 1984
A comparison between muscarinic receptor occupancy, adenylate cyclase inhibition, and inotropic response in human heart
M Delhaye, J M De Smet, G Taton, et al.
Page
of 66
Search research articles
Search
Showing results (481-490 of 651) with videos related to
Sort By:
Page
of 66
The Journal of Clinical Endocrinology and Metabolism
|
November 1, 1993
Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas
P Robberecht, P Vertongen, B Velkeniers, et al.
European Journal of Biochemistry
|
January 30, 1991
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes
P Gourlet, M C Woussen-Colle, P Robberecht, et al.
Human Molecular Genetics
|
December 10, 2019
Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy
Antina de Boer, Annet Storm, Maricel Gomez-Soler, et al.
The New England Journal of Medicine
|
June 11, 2005
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
Gert Van Assche, Marc Van Ranst, Raf Sciot, et al.
FEBS Letters
|
March 12, 1990
Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J
L Buscail, P Gourlet, A Cauvin, et al.
Peptides
|
July 1, 1990
The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK
A Cauvin, L Buscail, P Gourlet, et al.
British Journal of Pharmacology
|
June 24, 2000
Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition
J Van Rampelbergh, M G Juarranz, J Perret, et al.
Molecular Pharmacology
|
September 1, 1983
The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors
P Robberecht, M Delhaye, G Taton, et al.
Cellular Signalling
|
December 1, 2001
Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors
M G Juarranz, O Bolaños, I Gutiérrez-Cañas, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
February 1, 1984
A comparison between muscarinic receptor occupancy, adenylate cyclase inhibition, and inotropic response in human heart
M Delhaye, J M De Smet, G Taton, et al.
Page
of 66